Impact of the primary tumor location on secondary sites and overall mortality in patients with metastatic upper tract urothelial carcinoma | | 2022 |
Validation and Application of MD Anderson Symptom Inventory Module for Patients with Bladder Cancer in the Perioperative Setting | | 2022 |
Resolution of the expert council “Modern options for the treatment of urothelial cancer” | | 2022 |
Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis | | 2022 |
Urethral Cancer After Urethroplasty: A Case Report and Review of the Literature | | 2022 |
Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors | Urologic Oncology: Seminars and Original Investigations | 2022 |
Reply to: Comments on "Neoadjuvant/Induction Combination Immunotherapy versus Combination Platinum‐based Chemotherapy for Locally Advanced (Stage III) Urothelial Cancer." | International Journal of Cancer | |
The Impact of Neutrophil-to-Lymphocyte Ratio after Two Courses of Pembrolizumab for Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma | Biomedicines | 2022 |
PET-CT in Clinical Adult Oncology—IV. Gynecologic and Genitourinary Malignancies | Cancers | 2022 |
Insights on recent innovations in bladder cancer immunotherapy | Cancer Cytopathology | |
Real‐world treatment patterns and clinical outcomes of Japanese patients with non‐muscle invasive bladder cancer receiving intravesical bacillus Calmette–Guérin treatment | International Journal of Urology | |
Survival after Neoadjuvant/Induction Combination Immunotherapy versus Combination Platinum‐based Chemotherapy for Locally Advanced (Stage III ) Urothelial Cancer | International Journal of Cancer | |
Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma: The potential impact of informative censoring. | Cancer | 2022 |
Cost-Effectiveness Analysis of Hepatic Arterial Infusion Chemotherapy of Infusional Fluorouracil, Leucovorin, and Oxaliplatin Versus Transarterial Chemoembolization in Patients With Large Unresectable Hepatocellular Carcinoma. | Frontiers in Pharmacology | 2022 |
Head-to-Head Comparison of the Expression Differences of NECTIN-4, TROP-2, and HER2 in Urothelial Carcinoma and Its Histologic Variants. | Frontiers in Oncology | 2022 |
MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. | Nature Communications | 2022 |
Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder Cancer. | Cancers | 2022 |
Management of Advanced Urothelial Carcinoma in Older and Frail Patients: Have Novel Treatment Approaches Improved Their Care? | Drugs and Aging | 2022 |
Impact of neoadjuvant chemotherapy on survival and recurrence patterns after robot-assisted radical cystectomy for muscle-invasive bladder cancer: Results from the International Robotic Cystectomy Consortium. | International Journal of Urology | 2021 |
Efficacy of Surgery on the Primary Tumour in Patients with Metastatic Bladder Cancer: A Comprehensive Review | Bladder Cancer | 2022 |
Uptake of re-resection in T1 bladder cancer: An interrupted population-based time series analysis among different groups of surgeons. | Urologic Oncology: Seminars and Original Investigations | 2022 |
Immune-Checkpoint Inhibitors in Advanced Bladder Cancer: Seize the Day. | Biomedicines | 2022 |
Digital ischaemia and necrosis from oxaliplatin. | BMJ Case Reports | 2022 |
New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond. | Cells | 2022 |
Neoadjuvant and Adjuvant Therapy for Muscle-Invasive Bladder Cancer | | 2022 |
Impact of FDG- PET CT in the Management of Muscle Invasive Bladder Cancer. | Clinical Genitourinary Cancer | 2022 |
Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis. | European Urology | 2022 |
Re: Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. | European Urology | 2022 |
Management of Patients With Advanced Urothelial Carcinoma in an Evolving Treatment Landscape: A Qualitative Study of Provider Perspectives of First-Line Therapies. | Clinical Genitourinary Cancer | 2021 |
A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy. | Advances in Radiation Oncology | 2022 |
Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials | European Urology | 2021 |
Upper Tract Urothelial Carcinoma | | 2021 |
Intravesical Therapy for Non-muscle Invasive Urothelial Carcinoma | | 2021 |
Medical Oncology | | 2008 |
Contemporary Trends and Efficacy of Pelvic Lymph Node Dissection at Radical Cystectomy for Urothelial and Variant Histology Carcinoma of the Urinary Bladder. | Clinical Genitourinary Cancer | 2021 |
Latest progress in molecular biology and treatment in genitourinary tumours | Clinical and Translational Oncology | 2020 |
Validity of using cancer registry data for comparative effectiveness research | | |
Metastatic Nodal Pattern: Is There a Role for Paraaortic Lymph Node Dissection | | 2018 |
Integrating chemotherapy and radiotherapy for bladder cancer | | |
Impact of health services on compliance and outcomes | | |
The Role of Lymphadenectomy in the Management of Urothelial Carcinoma of the Upper Urinary Tract | | 2015 |
Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma | Clinical Genitourinary Cancer | 2021 |
Oncological benefit of re-resection for T1 bladder cancer: a comparative effectiveness study | BJU International | 2021 |
Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States | Advances in Therapy | 2021 |
Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for urothelial cell carcinoma of the urinary bladder 2017 | Urology Annals | 2018 |
Prognostic role of delay before radical cystectomy: retrospective analysis of a single-centre cohort with 376 patients | Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology | 2018 |
Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR) | ClinicoEconomics and Outcomes Research | 2020 |
Incidence of upper tract urothelial carcinoma in Spain | Actas Urológicas Españolas | 2020 |
Antibody-Drug Conjugates in Urothelial Carcinomas | Current Oncology Reports | 2020 |
Treatment Overview | | 2017 |